Covid-19 roundup: Mod­er­na read­ies to en­ter PhI­II in Ju­ly, As­traZeneca not far be­hind; EU ready to ne­go­ti­ate vac­cine ac­cess with $2.7B fund

Mod­er­na may soon add an­oth­er first to the Covid-19 vac­cine race.

In March, the mR­NA biotech was the first com­pa­ny to put a Covid-19 vac­cine in­to hu­mans. Next month, they may be­come the first com­pa­ny to put their vac­cine in­to the large, late-stage tri­als that are need­ed to prove whether the vac­cine is ef­fec­tive.

In an in­ter­view with JA­MA ed­i­tor Howard Bauch­n­er, NI­AID chief An­tho­ny Fau­ci said that a 30,000-per­son, Phase III tri­al for Mod­er­na’s vac­cine could start in Ju­ly. The news comes a week af­ter Mod­er­na be­gan a Phase II study that will en­roll sev­er­al hun­dred peo­ple.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.